American Diabetes Association.Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S42.
2.
American Association of Clinical Endocrinologists.Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management—2002 update. Endocr Pract.2002;8(suppl 1):40-83.
3.
IDF Clinical Guidelines Task Force.Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation; 2005.
4.
Monnier L., Lapinski H., Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care. 2003;26:881-885.
5.
Humalog® (insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; August 2004.
6.
NovoLog® (insulin aspart [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; October 2005.
7.
Apidra® (insulin glulisine [rDNA origin] injection) [prescribing information]. Kansas City, Mo: Aventis Pharmaceuticals; November 2005.
8.
Rolla ARInsulin analog mixes in the management of type 2 diabetes. Pract Diabetol. 2004;21:1-7.
9.
Heinemann L. , Weyer C., Rauhaus M., et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21:1910-1914.
10.
Mudaliar SR , Lindberg FA, Joyce M., et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-1506.
11.
Lantus® (insulin glargine [rDNA origin] injection) [prescribing information]. Kansas City, Mo: Aventis Pharmaceuticals; February 2006.
12.
Levemir® (insulin detemir [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; October 2005.
13.
Saydah SH, Fradkin J., Cowie CCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA.2004;291:335-342.
14.
Guidelines on minimal basic care for persons with diabetes. International Journal of Diabetes in Developing Countries.2000;20:1-7.
15.
Riddle MC, Rosenstock J., Gerich J.The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care.2003;26:3080-3086.
16.
Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
17.
NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; November 2005.
18.
Humalog® Mix75/25™ (75% insulin lispro protamine suspension and 25% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; March 2005.
19.
Humalog® Mix50/50™ (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; January 2006.
20.
Garber AJ, Wahlen J., Wahl T., et al. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 Study). Diabetes Obes Metab. 2006;8:58-66.
21.
Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
